Abstract:
The invention is directed to compositions and methods of using the same for the prevention and treatment of hypoxic conditions, ischemia/reperfusion injury and the sequels thereof.
Abstract:
The invention is concerned with a pharmaceutical composition consisting of two or more components, where at least one component binds to VE-cadherin and prevents capillary leak, tissue edema formation and acute inflammation and at least one other component activates the RISK pathway and/or prevents the opening of the mitochondrial permeability transition pore (MPTP).
Abstract:
Peptides and derivatives thereof of the following general formula (I): H 2 N-GHRPX 1 X 2 PX 3 X 4 X 5 PX 6 PPPX 7 X 8 X 9 X 10 B(1)B(2)B(3)-X 11 , wherein: B(1) denotes either a chemical bond or the amino acid G; B(2) denotes either a chemical bond or the amino acid Y; B(3) denotes either a chemical bond or the amino acid R. X 1 - X 10 denote one of the 20 genetically encoded amino acids, X 11 denotes OR 1 with R 1 = hydrogen or (C 1 -C 10 -alkyl), or NR 2 R 3 , R 2 and R 3 being identical or different and denoting hydrogen, (C 1 -C 10 )-alkyl, or a residue -PEG 5-60K , wherein the PEG-residue is linked to the N atom via a spacer, or a residue NH-Y-Z-PEG 5-60K , wherein Y denotes a chemical bond or a genetically coded amino acid from among the group of S, C, K or R, and Z denotes a spacer by way of which a polyethylene glycol (PEG)-residue may be linked, as well as the physiologically acceptable salts thereof.
Abstract:
A method of screening for compounds out of the group consisting of proteins, peptides, peptidomimetics, antibodies or small organic molecules that increase the activity of the protein Rac1 by virtue of their binding to the extracellular portion of this protein, the method comprising the steps of: a) contacting a confluent layer of cultured endothelial cells grown on porous membranes with at least one of the test compounds alone or together with a stimulant of vascular permeability, b) measuring the endothelial permeability with a suitable agent, which can be colorimetrically detected.
Abstract:
Die Erfindung betrifft ein Verfahren zur Formierung eines organischen Pigments, bei dem man das Pigment in einem wässrigen Lösungsmittel oder einer Mineralsäure löst oder dispergiert und aus der Lösung oder Dispersion in Gegenwart eines Kristallisationsmodifikators kristallisieren lässt und anschließend als Feststoff isoliert, wobei der Kristallisationsmodifikator ein Sulfonatgruppen aufweisendes Kondensationsprodukt aus mindestens einer Hydroxyarylsulfonsäure und/oder mindestens einer Hydroxydiarylsulfonverbindung und mindestens einem aliphatischen Aldehyd mit 1-6 C-Atomen, optional Harnstoff und gegebenenfalls einem Alkalisulfit, oder ein Gemisch aus derartigen Kondensationsprodukten ist.
Abstract:
Die Erfindung betrifft die Verwendung eines Peptids, umfassend die N-terminale Sequenz Gly-His-Arg-Pro-Leu-Asp-Lys-Lys-Arg-Glu-Glu-Ala-Pro-Ser-Leu-Arg-Pro-Ala- Pro-Pro-Pro-Ile-Ser-Gly-Gly-Gly-Tyr-Arg oder irgendeiner allelen Variante oder Derivats dieses Peptids, welche bzw. welches die biologische Eigenschaft besitzt, mit dem induzierbaren VE-Cadherin-Bindungsmotiv an der Bβ-Kette (d.h. Bβ 15-42 ) des menschlichen Fibrins zusammenzupassen, für die Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Schock, genauer gesagt eines hämorrhagischen Schocks.
Abstract:
A coating formed on a substrate is provided which coating comprises (a) an organic NIR-transparent pigment and/or an inorganic NIR-reflective pigment; (b) a dye having a transmittance of at least 75% in the range of from 700 to 2500 nm; and (c) optionally an effect pigment; wherein said coating exhibits a total solar reflectance (TSR) of (i) ≥ 40%, if 60
Abstract:
The invention relates to a method for the formation of an organic pigment, wherein the pigment is dissolved or dispersed in an aqueous solvent or a mineral acid and is allowed to crystallize from the solution or dispersion in the presence of a crystallization modifier and is subsequently isolated as a solid, wherein the crystallization modifier is a condensation product of at least one hydroxyaryl sulfonic acid having sulfonate groups and/or at least one hydroxydiaryl sulfone compound and at least one aliphatic aldehyde with 1-6 carbon atoms, optionally containing urea and possibly an alkali sulfite, or a mixture of such condensation products.
Abstract:
The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides.
Abstract:
The invention relates to peptides and peptide derivatives of the following general Formulas (Ia) and (Ib) as well as in particular anti-inflammatory drugs containing these peptides.